Diabetes News / Recent Literature Review / Forth Quarter 2019
DOI:
https://doi.org/10.2015/hc.v15i1.886Abstract
Association of Metabolic Surgery With Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes and Obesity
In this observational retrospective study, 2287 patients with obesity (BMI≥30 ) and type 2 diabetes who underwent metabolic surgery within the Cleveland Clinic Health System, were matched 1:5 to nonsurgical patients with diabetes and obesity.
The primary end point was the incident of extended major adverse cardiovascular events (MACE, composite of 6 outcomes), defined a first all-cause mortality, coronary artery events, cerebrovascular events, heart failure, nephropathy and atrial fibrillation. Secondary outcome included 3-component MACE (myocardial infarction, ischemic stroke and mortality). The median follow-up duration was 3.9 years. At the end of the study period, 385 (30.8%) patients in the surgical group and 3243 (44.7%) patients in the nonsurgical group experienced a primary end point (hazard ratio, HR 0.61, 95% CI, 0.55 – 0.69). All secondary putcomes showed significantly differences in favor of metabolic surgery. All-cause mortality occurred in 112 patients in the metabolic surgery group and 1111 patients in the nonsurgical group (HR = 0.59, 95%CI, 0.48- 0.72). Metabolic surgery was also associated with a significant reduction of HbA1c (mean difference between groups1.1%), and use of noninsulin diabetes medication, insulin antihypertensive medications and lipid0lower therapies. In the 90 days after metabolic surgery, complications included bleeding requiring transfusion (n=68, 3.0 %), pulmonary adverse events (n=58, 2.5%), venous thromboembolism (n=4, 0.2%), cardiac events (n=17, 0.7%), and renal failure requiring dialysis (n=4, 0.2%) (Aminlan A et al, JAMA 2019;322:1271-1282).
Downloads
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).